Article Per Year (5 Year)
p-Index From 2019 - 2024
0.61
P-Index
This Author published in this journals
All Journal Metamorfosis Journal of Economic, Bussines and Accounting (COSTING) Health Information : Jurnal Penelitian
Johansen Johansen
Unknown Affiliation
Dentistry Economics, Econometrics & Finance Education Health Professions Medicine & Pharmacology Nursing Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Health Information : Jurnal Penelitian

 1 
Potensi Penggunaan Agen Anti-Fungal Naftifine Sebagai Terapi Inovatif Tinea: Sebuah Tinjauan Literatur Titanic, Pussof Yayazucah; Arliska, Vira Geraldine; Johansen, Johansen; Kentanto, Given; Priyanto, Teguh
Health Information : Jurnal Penelitian Content Digitized
Publisher : Poltekkes Kemenkes Kendari

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

A disease with the first name "Tinea" is aninfection caused by the presence of dermatophyte fungi that can occur invarious locations of the body. Tinea corporis is a superficial fungalskin infection of the body caused by dermatophytes, specifically on thetrunk, neck, arms and legs. Other forms of tinea infection based on itslocation are on the scalp (tinea capitis), face (tinea faciei), hands(tinea manuum), groin (tinea cruris), and feet (tinea pedis). Ingeneral, there are 3 genera that can cause this condition ofdermatophytosis (tinea), namely the genera Trichophyton, Epidermophyton,and Microsporum. Currently, there are various topical anti-fungal agentsfor treating dermatophytosis (tinea). The two main classes thatrepresent the majority of available topical antifungal agents are azolesand allylamines. Overall, the allylamines (naftifine) are superior tothe azoles in activity against dermatophytes, although both areclinically effective. Therefore, in this literature review, we conductedan analysis of the effects of using naftifine in treating various typesof tinea. Study searches were conducted on various databases such asPubmed, ScienceDirect, Directory of Open Access Journals, and theCochrane Library. From the search results obtained a total of 212studies. The studies that met the inclusion and exclusion criteria werethe 3 studies analyzed in this literature review. Administration ofNaftifine showed a higher mycological cure rate, therapeuticeffectiveness, clinical symptoms, and cure rate than the control group.No adverse events were reported with any type of naftifine in allinclusion studies. Administration of naftifine is a therapy with sideeffects in treating various types of tinea(dermatophytosis).
Penggunaan Eculizumab sebagai Pilihan Terapi pada Pasien HUS dengan Transplantasi Ginjal Tria Nursyifa, Ilma; Dewanti, Puspa; Inggerit, Inggerit; Johansen, Johansen; Regina, Sylvia
Health Information : Jurnal Penelitian Content Digitized
Publisher : Poltekkes Kemenkes Kendari

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Latar Belakang: Hemolytic Uremic Syndrome (HUS) adalah bentuk trombotik mikroangiopati yang ditandai dengan trombositopenia, anemia hemolitik mikroangiopati dan gagal ginjal akut, serta dapat terjadi baik pada anak anak maupun orang dewasa. Eculizumab adalah antibodi monoklonal chimeric IgG2/4 yang berpasangan dengan protein komplemen C5 dan digunakan untuk mengobati atau mencegah kekambuhan HUS setelah transplantasi ginjal. Tujuan: Artikel ini bertujuan untuk mengetahui penggunaan eculizumab sebagai pilihan terapi pada pasien HUS yang telah menjalani transplantasi ginjal mengenai dampak dan cara pemberianya. Metode: Tinjauan literatur dari dua database yaitu Google Scholar dan PubMed yang terbit dalam rentang waktu 5 tahun  yaitu dari tahun 2018-2023. Hasil: Didapatkan 11 literatur yang membuktikan eculizumab dapat dipertimbangkan sebagai pilihan terapi pada pasien HUS dengan transplantasi ginjal. Dampak eculizumab dapat menurunkan risiko kekambuhan atau timbulnya HUS pasca transplantasi ginjal. Walaupun kebanyakan efek samping pemberian eculizumab tidak serius, meningitis hingga kematian tidak dapat dikesampingkan. Maka dibutuhkan pedoman tatacara penggunaan eculizumab berdasarkan data yang lebih besar untuk mengurangi risiko infeksi dan memangkas biaya.
Co-Authors Aluisius Hery Pratono Arliska, Vira Geraldine Dewanti, Puspa Inggerit, Inggerit Kentanto, Given Priyanto, Teguh Regina, Sylvia Titanic, Pussof Yayazucah Tria Nursyifa, Ilma